Cardiovascular Drugs

Cardiovascular Drugs Comprehensive Study by Type (Anticoagulants or blood thinners, Antiplatelet agents, Thrombolytic agents, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Other), Application (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Other), Diseases (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others), End User (Hospital, Clinic, Other) Players and Region - Global Market Outlook to 2026

Cardiovascular Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Cardiovascular Drugs Market Scope
Cardiovascular drug, any agent that affects the function of the heart and blood vessels. Drugs that act on the cardiovascular system are among the most widely used in medicine. Examples of disorders in which such drugs may be useful include hypertension (high blood pressure), angina pectoris (chest pain resulting from inadequate blood flow through the coronary arteries to the heart muscle), heart failure (inadequate output of the heart muscle in relation to the needs of the rest of the body), and arrhythmias (disturbances of cardiac rhythm).

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledBristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Bayer AG (Germany), Janssen Pharmaceuticals, Inc. (Belgium), AstraZeneca (United Kingdom), Sanofi (France), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Gilead Sciences, Inc. (United States) and F. Hoffmann-La Roche Ltd (Switzerland)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cardiovascular Drugs market throughout the predicted period.

Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Bayer AG (Germany), Janssen Pharmaceuticals, Inc. (Belgium), AstraZeneca (United Kingdom), Sanofi (France), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Gilead Sciences, Inc. (United States) and F. Hoffmann-La Roche Ltd (Switzerland) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Cardiovascular Drugs market by Type , by Application (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies and Other) and Region with country level break-up.

On the basis of geography, the market of Cardiovascular Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.




Influencing Trend:
Increasing Investment In RD Activities In Development Of Cardiovascular Drugs

Market Growth Drivers:
Increasing Heart Disease Population

Challenges:
High Cost Associated To Cardiovascular Drugs

Restraints:
Rise In Cases Of Side Effects Of Cardiovascular Drugs

Opportunities:
Growing Health Care Infrastructure In Develop Region and Favorable Government Incentive Treatment of Cardiovascular

Key Target Audience
Cardiovascular Drugs Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Anticoagulants or blood thinners
  • Antiplatelet agents
  • Thrombolytic agents
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin II receptor blockers (ARBs)
  • Other
By Application
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other
By Diseases
  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By End User
  • Hospital
  • Clinic
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Heart Disease Population
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated To Cardiovascular Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment In RD Activities In Development Of Cardiovascular Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cardiovascular Drugs, by Type, Application, Diseases , End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Cardiovascular Drugs (Value)
      • 5.2.1. Global Cardiovascular Drugs by: Type (Value)
        • 5.2.1.1. Anticoagulants or blood thinners
        • 5.2.1.2. Antiplatelet agents
        • 5.2.1.3. Thrombolytic agents
        • 5.2.1.4. Angiotensin-converting enzyme (ACE) inhibitors
        • 5.2.1.5. Angiotensin II receptor blockers (ARBs)
        • 5.2.1.6. Other
      • 5.2.2. Global Cardiovascular Drugs by: Application (Value)
        • 5.2.2.1. Retail Pharmacies
        • 5.2.2.2. Hospital Pharmacies
        • 5.2.2.3. Online Pharmacies
        • 5.2.2.4. Other
      • 5.2.3. Global Cardiovascular Drugs by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Other
      • 5.2.4. Global Cardiovascular Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cardiovascular Drugs (Price)
      • 5.3.1. Global Cardiovascular Drugs by: Type (Price)
  • 6. Cardiovascular Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Gilead Sciences, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cardiovascular Drugs Sale, by Type, Application, Diseases , End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Cardiovascular Drugs (Value)
      • 7.2.1. Global Cardiovascular Drugs by: Type (Value)
        • 7.2.1.1. Anticoagulants or blood thinners
        • 7.2.1.2. Antiplatelet agents
        • 7.2.1.3. Thrombolytic agents
        • 7.2.1.4. Angiotensin-converting enzyme (ACE) inhibitors
        • 7.2.1.5. Angiotensin II receptor blockers (ARBs)
        • 7.2.1.6. Other
      • 7.2.2. Global Cardiovascular Drugs by: Application (Value)
        • 7.2.2.1. Retail Pharmacies
        • 7.2.2.2. Hospital Pharmacies
        • 7.2.2.3. Online Pharmacies
        • 7.2.2.4. Other
      • 7.2.3. Global Cardiovascular Drugs by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Other
      • 7.2.4. Global Cardiovascular Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cardiovascular Drugs (Price)
      • 7.3.1. Global Cardiovascular Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cardiovascular Drugs: by Type(USD Million)
  • Table 2. Cardiovascular Drugs Anticoagulants or blood thinners , by Region USD Million (2016-2021)
  • Table 3. Cardiovascular Drugs Antiplatelet agents , by Region USD Million (2016-2021)
  • Table 4. Cardiovascular Drugs Thrombolytic agents , by Region USD Million (2016-2021)
  • Table 5. Cardiovascular Drugs Angiotensin-converting enzyme (ACE) inhibitors , by Region USD Million (2016-2021)
  • Table 6. Cardiovascular Drugs Angiotensin II receptor blockers (ARBs) , by Region USD Million (2016-2021)
  • Table 7. Cardiovascular Drugs Other , by Region USD Million (2016-2021)
  • Table 8. Cardiovascular Drugs: by Application(USD Million)
  • Table 9. Cardiovascular Drugs Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 10. Cardiovascular Drugs Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 11. Cardiovascular Drugs Online Pharmacies , by Region USD Million (2016-2021)
  • Table 12. Cardiovascular Drugs Other , by Region USD Million (2016-2021)
  • Table 13. Cardiovascular Drugs: by End User(USD Million)
  • Table 14. Cardiovascular Drugs Hospital , by Region USD Million (2016-2021)
  • Table 15. Cardiovascular Drugs Clinic , by Region USD Million (2016-2021)
  • Table 16. Cardiovascular Drugs Other , by Region USD Million (2016-2021)
  • Table 17. South America Cardiovascular Drugs, by Country USD Million (2016-2021)
  • Table 18. South America Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 19. South America Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 20. South America Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 21. South America Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 22. Brazil Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 23. Brazil Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 24. Brazil Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 25. Brazil Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 26. Argentina Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 27. Argentina Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 28. Argentina Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 29. Argentina Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 30. Rest of South America Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 31. Rest of South America Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 32. Rest of South America Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 33. Rest of South America Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 34. Asia Pacific Cardiovascular Drugs, by Country USD Million (2016-2021)
  • Table 35. Asia Pacific Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 36. Asia Pacific Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 37. Asia Pacific Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 38. Asia Pacific Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 39. China Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 40. China Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 41. China Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 42. China Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 43. Japan Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 44. Japan Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 45. Japan Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 46. Japan Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 47. India Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 48. India Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 49. India Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 50. India Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 51. South Korea Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 52. South Korea Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 53. South Korea Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 54. South Korea Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 55. Taiwan Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 56. Taiwan Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 57. Taiwan Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 58. Taiwan Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 59. Australia Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 60. Australia Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 61. Australia Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 62. Australia Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 67. Europe Cardiovascular Drugs, by Country USD Million (2016-2021)
  • Table 68. Europe Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 69. Europe Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 70. Europe Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 71. Europe Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 72. Germany Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 73. Germany Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 74. Germany Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 75. Germany Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 76. France Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 77. France Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 78. France Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 79. France Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 80. Italy Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 81. Italy Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 82. Italy Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 83. Italy Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 84. United Kingdom Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 85. United Kingdom Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 86. United Kingdom Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 87. United Kingdom Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 88. Netherlands Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 89. Netherlands Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 90. Netherlands Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 91. Netherlands Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 92. Rest of Europe Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 93. Rest of Europe Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 94. Rest of Europe Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 95. Rest of Europe Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 96. MEA Cardiovascular Drugs, by Country USD Million (2016-2021)
  • Table 97. MEA Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 98. MEA Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 99. MEA Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 100. MEA Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 101. Middle East Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 102. Middle East Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 103. Middle East Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 104. Middle East Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 105. Africa Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 106. Africa Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 107. Africa Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 108. Africa Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 109. North America Cardiovascular Drugs, by Country USD Million (2016-2021)
  • Table 110. North America Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 111. North America Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 112. North America Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 113. North America Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 114. United States Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 115. United States Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 116. United States Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 117. United States Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 118. Canada Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 119. Canada Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 120. Canada Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 121. Canada Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 122. Mexico Cardiovascular Drugs, by Type USD Million (2016-2021)
  • Table 123. Mexico Cardiovascular Drugs, by Application USD Million (2016-2021)
  • Table 124. Mexico Cardiovascular Drugs, by Diseases USD Million (2016-2021)
  • Table 125. Mexico Cardiovascular Drugs, by End User USD Million (2016-2021)
  • Table 126. Cardiovascular Drugs: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Cardiovascular Drugs: by Type(USD Million)
  • Table 138. Cardiovascular Drugs Anticoagulants or blood thinners , by Region USD Million (2022-2027)
  • Table 139. Cardiovascular Drugs Antiplatelet agents , by Region USD Million (2022-2027)
  • Table 140. Cardiovascular Drugs Thrombolytic agents , by Region USD Million (2022-2027)
  • Table 141. Cardiovascular Drugs Angiotensin-converting enzyme (ACE) inhibitors , by Region USD Million (2022-2027)
  • Table 142. Cardiovascular Drugs Angiotensin II receptor blockers (ARBs) , by Region USD Million (2022-2027)
  • Table 143. Cardiovascular Drugs Other , by Region USD Million (2022-2027)
  • Table 144. Cardiovascular Drugs: by Application(USD Million)
  • Table 145. Cardiovascular Drugs Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 146. Cardiovascular Drugs Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 147. Cardiovascular Drugs Online Pharmacies , by Region USD Million (2022-2027)
  • Table 148. Cardiovascular Drugs Other , by Region USD Million (2022-2027)
  • Table 149. Cardiovascular Drugs: by End User(USD Million)
  • Table 150. Cardiovascular Drugs Hospital , by Region USD Million (2022-2027)
  • Table 151. Cardiovascular Drugs Clinic , by Region USD Million (2022-2027)
  • Table 152. Cardiovascular Drugs Other , by Region USD Million (2022-2027)
  • Table 153. South America Cardiovascular Drugs, by Country USD Million (2022-2027)
  • Table 154. South America Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 155. South America Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 156. South America Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 157. South America Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 158. Brazil Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 159. Brazil Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 160. Brazil Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 161. Brazil Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 162. Argentina Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 163. Argentina Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 164. Argentina Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 165. Argentina Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 166. Rest of South America Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 167. Rest of South America Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 168. Rest of South America Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 169. Rest of South America Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 170. Asia Pacific Cardiovascular Drugs, by Country USD Million (2022-2027)
  • Table 171. Asia Pacific Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 172. Asia Pacific Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 173. Asia Pacific Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 174. Asia Pacific Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 175. China Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 176. China Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 177. China Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 178. China Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 179. Japan Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 180. Japan Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 181. Japan Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 182. Japan Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 183. India Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 184. India Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 185. India Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 186. India Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 187. South Korea Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 188. South Korea Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 189. South Korea Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 190. South Korea Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 191. Taiwan Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 192. Taiwan Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 193. Taiwan Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 194. Taiwan Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 195. Australia Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 196. Australia Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 197. Australia Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 198. Australia Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 203. Europe Cardiovascular Drugs, by Country USD Million (2022-2027)
  • Table 204. Europe Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 205. Europe Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 206. Europe Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 207. Europe Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 208. Germany Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 209. Germany Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 210. Germany Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 211. Germany Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 212. France Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 213. France Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 214. France Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 215. France Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 216. Italy Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 217. Italy Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 218. Italy Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 219. Italy Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 220. United Kingdom Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 221. United Kingdom Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 222. United Kingdom Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 223. United Kingdom Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 224. Netherlands Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 225. Netherlands Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 226. Netherlands Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 227. Netherlands Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 228. Rest of Europe Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 229. Rest of Europe Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 230. Rest of Europe Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 231. Rest of Europe Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 232. MEA Cardiovascular Drugs, by Country USD Million (2022-2027)
  • Table 233. MEA Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 234. MEA Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 235. MEA Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 236. MEA Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 237. Middle East Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 238. Middle East Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 239. Middle East Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 240. Middle East Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 241. Africa Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 242. Africa Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 243. Africa Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 244. Africa Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 245. North America Cardiovascular Drugs, by Country USD Million (2022-2027)
  • Table 246. North America Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 247. North America Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 248. North America Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 249. North America Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 250. United States Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 251. United States Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 252. United States Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 253. United States Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 254. Canada Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 255. Canada Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 256. Canada Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 257. Canada Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 258. Mexico Cardiovascular Drugs, by Type USD Million (2022-2027)
  • Table 259. Mexico Cardiovascular Drugs, by Application USD Million (2022-2027)
  • Table 260. Mexico Cardiovascular Drugs, by Diseases USD Million (2022-2027)
  • Table 261. Mexico Cardiovascular Drugs, by End User USD Million (2022-2027)
  • Table 262. Cardiovascular Drugs: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cardiovascular Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Cardiovascular Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Cardiovascular Drugs: by End User USD Million (2016-2021)
  • Figure 7. South America Cardiovascular Drugs Share (%), by Country
  • Figure 8. Asia Pacific Cardiovascular Drugs Share (%), by Country
  • Figure 9. Europe Cardiovascular Drugs Share (%), by Country
  • Figure 10. MEA Cardiovascular Drugs Share (%), by Country
  • Figure 11. North America Cardiovascular Drugs Share (%), by Country
  • Figure 12. Global Cardiovascular Drugs: by Type USD/Units (2016-2021)
  • Figure 13. Global Cardiovascular Drugs share by Players 2021 (%)
  • Figure 14. Global Cardiovascular Drugs share by Players (Top 3) 2021(%)
  • Figure 15. Global Cardiovascular Drugs share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 23. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 24. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2021
  • Figure 25. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 27. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi (France) Revenue: by Geography 2021
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 31. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Gilead Sciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 35. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 37. Global Cardiovascular Drugs: by Type USD Million (2022-2027)
  • Figure 38. Global Cardiovascular Drugs: by Application USD Million (2022-2027)
  • Figure 39. Global Cardiovascular Drugs: by End User USD Million (2022-2027)
  • Figure 40. South America Cardiovascular Drugs Share (%), by Country
  • Figure 41. Asia Pacific Cardiovascular Drugs Share (%), by Country
  • Figure 42. Europe Cardiovascular Drugs Share (%), by Country
  • Figure 43. MEA Cardiovascular Drugs Share (%), by Country
  • Figure 44. North America Cardiovascular Drugs Share (%), by Country
  • Figure 45. Global Cardiovascular Drugs: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Bayer AG (Germany)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • AstraZeneca (United Kingdom)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Gilead Sciences, Inc. (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
Select User Access Type

Key Highlights of Report


Dec 2021 227 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Cardiovascular Drugs Quantitative research analysis
Cardiovascular Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Cardiovascular Drugs Market are by type [Anticoagulants or blood thinners, Antiplatelet agents, Thrombolytic agents, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs) and Other], by end use application [Retail Pharmacies, Hospital Pharmacies, Online Pharmacies and Other].
The Cardiovascular Drugs Market is gaining popularity and expected to see strong valuation by 2027.
  • Increasing Heart Disease Population

Know More About Cardiovascular Drugs Report?

Have a Query? Click Here

Other Related Reports

Bioactive Materials Comprehensive Study by Type (Glass, Ceramic, Composites, Others), Application (Pharmaceutical, Dentistry, Medical), Form (Powder, Moldable, Granules) Players and Region - Global M...
$ 3500
Chamomile Extract Comprehensive Study by Type (Chamaemelum Nobile, Marticaria Recutita), Application (Food And Beverages, Pharmaceuticals, Dietary Supplements, Personal Care/Cosmetics, Others), Grade...
$ 3650
Personalized Medicine Comprehensive Study by Type (Diagnostic, Therapeutics, Medical Care, Nutrition, Wellness), Application (Hospitals, Molecular Diagnostic Laboratories and Testing Centers, Academi...
$ 3750
Catalpol Comprehensive Study by Type (Purity: 99%, Purity: 96%, Other), Application (Medicine, Chemical Industry, Additive, Others), Packaging (25 mg, 50 mg, 100 mg, Others) Players and Region - Glob...
$ 3500
Desloratadine Comprehensive Study by Type (Injection, Freeze-dried powder), Application (Hospital use, Clinic, Others), Availability (1Mg (1.25 ml), 1.25 mg(2.5 ml), 5.0 mg), Form (Tablet, Oral solu...
$ 3450
Radiopharmaceutical Comprehensive Study by Type (Diagnostic Radioisotopes, Therapeutic Radioisotopes), Application (Oncology, Cardiology, Neurology, Thyroid), Procedures (Central Nervous System, Endo...
$ 3750